PrairieView Partners’s Bristol-Myers Squibb BMY Stock Holding History

PrairieView Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$37K	Hold	800	–	–	﹤0.01%	206
2025 Q1	$48K	Hold	800	–	–	0.01%	192
2024 Q4	$45K	Hold	800	–	–	﹤0.01%	203
2024 Q3	$41K	Sell	800 -495	-38%	-$23.2K	﹤0.01%	209
2024 Q2	$53K	Buy	1,295 +16	+1%	+$716	0.01%	198
2024 Q1	$70K	Buy	1,279 +6	+0.5%	+$306	0.01%	162
2023 Q4	$65K	Buy	1,273 +5	+0.4%	+$262	0.01%	161
2023 Q3	$73K	Buy	1,268 +4	+0.3%	+$245	0.01%	151
2023 Q2	$80K	Sell	1,264 -26	-2%	-$1.74K	0.01%	166
2023 Q1	$89K	Buy	1,290 +34	+3%	+$2.4K	0.01%	144
2022 Q4	$90K	Buy	1,256 +803	+177%	+$60.5K	0.01%	145
2022 Q3	$32K	Buy	453 +3	+0.7%	+$218	0.01%	212
2022 Q2	$35K	Hold	450	–	–	0.01%	223
2022 Q1	$33K	Hold	450	–	–	﹤0.01%	237
2021 Q4	$28K	Hold	450	–	–	﹤0.01%	262
2021 Q3	$27K	Hold	450	–	–	﹤0.01%	212
2021 Q2	$30K	Buy	450 +246	+121%	+$16K	﹤0.01%	198
2021 Q1	$13K	Buy	+204	New	+$12.7K	﹤0.01%	249

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PrairieView Partners's BMY Position: Q2 2025 in Review

PrairieView Partners held its Bristol-Myers Squibb (BMY) position steady in Q2 2025 at 800 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #206.

PrairieView Partners first reported a position in BMY in Q1 2021 and has held it in 18 quarters since. The position peaked at $90K in Q4 2022. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

PrairieView Partners held 800 shares of Bristol-Myers Squibb worth $37K as of Q2 2025.
PrairieView Partners left its Bristol-Myers Squibb share count unchanged in Q2 2025.
Bristol-Myers Squibb made up ﹤0.01% of PrairieView Partners's portfolio in Q2 2025, its #206 holding.
PrairieView Partners first reported a position in Bristol-Myers Squibb in Q1 2021 and has held it in 18 quarters since.
PrairieView Partners's Bristol-Myers Squibb position peaked at $90K in Q4 2022.
2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on PrairieView Partners's 13F filing for Q2 2025, filed 25 Jul 2025.